ClearPlasma SIGNED

Project "ClearPlasma" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Each year, almost 2 million people die from haemorrhaging, or blood loss. Massive blood loss can occur upon: Trauma, Surgery, Childbirth, Disseminated Intravascular Coagulation (DIC), Gastrointestinal Bleeding, etc. In all of these cases, there is an urgent need for efficient plasma transfusion to halt the bleeding. However, recent studies have shown that regular plasma fails to stop massive bleeding, while other treatments show low efficacy and increased mortality risk. ClearPlasma is an innovative filtration system that modifies human plasma to improve the treatment of massive bleeding and bleeding disorders. By extracting plasminogen, an important protein responsible for dissolving blood clots, ClearPlasma enhances coagulation and favours haemostasis, thus reducing bleeding of 55%. This translates into the opportunity to reduce up to 45% the units of plasma needed during transfusion, hence reducing treatment costs. ClearPlasma is a disposable filter that can be incorporated in current Apheresis systems thus not affecting common clinical practices. ClearPlasma addresses the Global Blood Transfusion Diagnostics Market, which was valued at approximately € 3.2bn in 2017, and is expected to reach around € 4.7bn by 2024, growing at a CAGR of 6.2% between 2018 and 2024. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of ClearPlasma and its market uptake.